

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/17909 A1

(51) International Patent Classification⁷: **A61K 31/353**

(21) International Application Number: PCT/KR01/00368

(22) International Filing Date: 9 March 2001 (09.03.2001)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
2000/46916 14 August 2000 (14.08.2000) KR

(71) Applicant (for all designated States except US): **KOREA INSTITUTE OF ORIENTAL MEDICINE** [KR/KR]; 4th Fl., Seshin Bldg., 129-11 Cheongdam-dong, Kangnam-gu, Seoul 135-765 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Chung-Sook** [KR/KR]; 4th Fl., Cheongam Bldg., 129-11 Cheongdam-dong, Kangnam-gu, 135-100 Seoul (KR). **HA, Hye-Kyung** [KR/KR]; 1-408 Seoul Garden Apartment, Dobong 1-dong, Dobong-gu, Seoul 132-017 (KR). **SONG, Kye-Yong** [KR/KR]; 922-6 Bangbae-dong, Seocho-gu, Seoul 137-061 (KR).

(74) Agent: **LEE, Han-Young**; 8th Fl., Seowon Bldg., 1675-1 Seocho-dong, Seocho-gu, Seoul 137-070 (KR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES

(57) Abstract: The present invention relates to a therapeutic agent of osteoporosis which comprises an active ingredient of quercetin derivatives. The quercetin derivatives of the invention can be practically applied for the treatment and prevention of osteoporosis, since they effectively inhibit osteoclast proliferation and stimulate osteoblast proliferation more than prior art therapeutic agents of osteoporosis, and increase trabecular bone area highly without changing hormone level in body and untoward effects on hematopoietic function and immune system.




WO 02/17909 A1

A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE
INGREDIENT OF QUERCETIN DERIVATIVES

5 BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a therapeutic agent
10 for osteoporosis which comprises an active ingredient of
quercetin derivatives, more specifically, to a therapeutic
agent for osteoporosis comprising an active ingredient of
quercetin derivatives represented by the following general
formula(I) which effectively stimulate osteoblast
15 proliferation and inhibit osteoclast proliferation.



20

Description of the Prior Art

Osteoporosis is a disease characterized by the
decrease of bone mass caused by mineral loss and the
25 subsequent expansion of marrow cavity. Bones become
brittle with the progress of the disease, and may be easily

fractured by a weak impact. Bone mass is affected by various factors such as genetic factors, nutritive condition, changes of hormone level, exercise and life style, and osteoporosis is known to be caused by aging, lack of exercise, low body weight, smoking, low calcium diet, menopause, and ovariectomy. In women, decrease of bone mass begins at the age of 30, and around menopause, concentration of estrogen rapidly decreases and vast amount of B-lymphocytes are accumulated by the similar mechanism to that of B-lymphocyte accumulation by IL-7(interleukin-7), and subsequent pre-B cell accumulation results in increased level of IL-6 which activates osteoclasts, thus, bone mass becomes decreased. In aged people, especially in women of postmenopause, osteoporosis is not the avoidable disease although the severity of the symptom may vary, therefore, many research groups and pharmaceutical companies have made a great deal of efforts for development of therapeutic agents for bone diseases to prevent and treat osteoporosis upon an increase of elderly population.

Therapeutic agents for osteoporosis now being used include estrogen preparations, androgenic anabolic steroid preparations, calcium supplements, phosphate preparations, fluoride preparations, ipriflavone, vitamin D3, etc. In recent years, novel drugs for osteoporosis have been developed, which include Aminobisphosphonate by Merck Co.(U.S.A.) in 1995 and Raloxifene which plays a role of selective estrogen receptor modulator(SERM) by Eli Lilly Co.(U.S.A.) in 1997.

Therapeutic agents for osteoporosis mentioned above are mostly estrogen substances which are known to cause adverse side effects such as cancer, cholelithiasis, and thrombosis. Since long term administration of drug is inevitable in the treatment of osteoporosis, there is a continuing need to develop novel effective agents which can replace estrogen with high safety even when administered for a prolonged period of time.

As estrogen substitutes, phytoestrogens such as soybean isoflavone have been reported. Phytoestrogen, first reported in 1946, was found interim of verifying the cause of clover disease which was named for the high increase(over 30%) of infertility of the sheep fed with red clover(*Trifolium subterraneum* var. Dwalganup). The cause of clover disease turned out to be an estrogen-like isoflavonoid contained in the plant, hence, the compound obtained from the plant has been named 'phytoestrogen'. After that, compounds reported as phytoestrogen includes isoflavone compounds such as daidzein, genistein, formononetin, and biochanin A, coumestan compounds such as coumestrol, lignan compounds such as enterolactone, and phenol compounds such as enterodiol. Such phytoestrogens exist mostly in the form of aglycone, 6'-O-acetylglucoside or 6'-O-malonylglucoside, and daidzein and genistein exist in the form of 7-O-glucoside. Among aforementioned compounds, glucosides are known to be hydrolysed with enterobacteria or gastric acid and absorbed in the form of aglycone which is a free isoflavone. The researches have revealed that the said phytoestrogens function similarly to the animal estrogens. That is, the phytoestrogen inhibit proliferation of breast cancer cells by binding to the estrogen receptor and have been reported to be used as the estrogen substitute for the treatment of cardiovascular diseases and other symptoms occurring in the postmenopause women. However, the said phytoestrogens are not widely used for the treatment and prevention of osteoporosis due to the insufficient pharmaceutical effectiveness and high cost required for the isolation and purification from natural products.

Under the circumstances, are strong reasons for developing and exploring alternative compounds with safety and effectiveness for the treatment and prevention of osteoporosis, which can be prepared in an economical manner.


SUMMARY OF THE INVENTION

The present inventors have made an effort to develop an effective substitute agent for the treatment and prevention of osteoporosis, which is safe and economical, and have found that chemically synthesized quercetin derivatives have activities of stimulating osteoblast proliferation and inhibiting osteoclast proliferation, without any adverse side effects on internal organs, thus, quercetin derivative can be employed as an active ingredient of a therapeutic agent for osteoporosis.

A primary object of the present invention is, therefore, to provide a therapeutic agent for osteoporosis which comprises an active ingredient of quercetin derivatives.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a therapeutic agent for osteoporosis which comprises an active ingredient of quercetin derivatives represented by the following general formula(I) and pharmaceutically acceptable carriers:



25

wherein,

R_1 is gentiotriose, glucopyranose, O-arabinofuranose, O-diglucofuranose, O-galactopyranose, O-galactoside-gallate, O-gentiobiose, O-glucopyranose, O-glucuronide, O-neohesperidose, O-rhamnopyranose, O-rutinose,
 5 O-sophorose, O-xylopyranose, OCH_3 , OH, rhamnogentiobiose, rhamnoglucofuranose or sulfate;

R_2 is OH or O-glucopyranose;

R_3 is OCH_3 , OH, O-glucopyranose, O-glucuronopyranose or glucopyranose;

10 R_4 is OCH_3 or OH; and,

R_5 is OCH_3 , OH, O-glucopyranose or O-glucose.

Among the quercetin derivatives represented by general formula(I), well-known compounds are classified as
 15 follows: (i) a derivative group of the formula I wherein R_2 to R_5 are OH and R_1 varies, includes quercetin where R_1 is OH, avicularoside where R_1 is O- α -L-arabinofuranose, guaijaverin where R_1 is O-arabinopyranose, hyperoside where R_1 is O- β -D-galactopyranose, isohyperoside where R_1 is O- β -
 20 D-galactopyranose, isoquercitrin where R_1 is O-glucopyranose, multinoside A where R_1 is O- $[\beta$ -D-glucopyranosyl-(1-4)- α -L-rhamnopyranose], multinoside A acetate where R_1 is (6-O-acetyl)- β -D-glucopyranosyl-(1-4)- α -L-rhamnopyranose, quercitrin where R_1 is O- α -L-
 25 rhamnopyranose, rutin where R_1 is O- β -D-rutinose, quercetin-3-O-(2"-O- β -D-glucopyranosyl)- α -L-rhamnopyranoside where R_1 is O-(2"-O- β -D-glucopyranosyl)- α -L-rhamnopyranose, quercetin-3-O-(6"-O-galloyl)-
 glucopyranoside where R_1 is O-(6"-O-galloyl)-glucopyranose,
 30 quercetin-3-O-(6'"-O-p-coumaroyl- β -D-glucopyranosyl-(1-2)- α -L-rhamnopyranoside) where R_1 is O-(6'"-O-p-coumaroyl- β -D-glucopyranosyl-(1-2)- α -L-rhamnopyranose, quercetin-3-O-D-glucopyranosyl-(1-6)- β -D-glucopyranosyl-(1-4)- α -L-
 35 rhamnopyranoside where R_1 is O-D-glucopyranosyl-(1-6)- β -D-glucopyranosyl-(1-4)- α -L-rhamnopyranose, quercetin-3-O-[2"-O-6'"-O-p-(7'"-O- β -D-glucopyranosyl)coumaroyl- β -D-glucopyranosyl]- α -L-rhamnopyranoside where R_1 is O-[2"-O-

6'-O-p-(7"-O-β-D-glucopyranosyl) coumaroyl-β-D-glucopyranosyl]-α-L-rhamnopyranose, quercetin-3-O-[6'-p-coumaroyl-β-D-glucopyranosyl-β-(1-4)-rhamnopyranoside] where R₁ is O-[6'-p-coumaroyl-β-D-glucopyranosyl-β-(1-4)-rhamnopyranose], quercetin-3-O-[α-L-rhamnopyranosyl(1-2)-α-L-rhamnopyranosyl-(1-6)-β-D-glucopyranoside] where R₁ is O-[α-L-rhamnopyranosyl(1-2)-α-L-rhamnopyranosyl-(1-6)-β-D-glucopyranose], quercetin-3-O-[α-rhamnopyranosyl(1-4)α-L-rhamnopyranosyl(1-6)β-D-galactopyranoside] where R₁ is O-[α-rhamnopyranosyl(1-4)α-L-rhamnopyranosyl(1-6)β-D-galactopyranose], quercetin-3-O-[α-rhamnopyranosyl-(1-2)]-[β-glucopyranosyl-(1-6)]-β-D-galactopyranoside where R₁ is O-[α-rhamnopyranosyl-(1-2)]-[β-glucopyranosyl-(1-6)]-β-D-galactopyranose, quercetin-3-O-[α-rhamnopyranosyl-(1-4)-α-rhamnopyranosyl-(1-6)-β-galactopyranoside] where R₁ is O-[α-rhamnopyranosyl-(1-4)-α-rhamnopyranosyl-(1-6)-β-galactopyranose], quercetin-3-O-α-L-rhamnopyranosyl-(1-2)-β-D-galactopyranoside where R₁ is O-α-L-rhamnopyranosyl-(1-2)-β-D-galactopyranose, quercetin-3-O-β-D-diglucopyranoside where R₁ is O-β-D-diglucopyranose, quercetin-3-O-β-D-galactoside-2"-gallate where R₁ is O-β-D-galactoside-2"-gallate, quercetin-3-O-β-D-glucopyranoside-(1-6)-β-D-galactopyranoside where R₁ is O-β-D-glucopyranoside-(1-6)-β-D-galactopyranose, quercetin-3-O-β-D-glucopyranosyl-(1-3)-α-L-rhamnopyranosyl-(1-6)-β-D-galactopyranoside where R₁ is O-β-D-glucopyranosyl-(1-3)-α-L-rhamnopyranosyl-(1-6)-β-D-galactopyranose, quercetin-3-O-β-D-glucuronide where R₁ is O-β-D-glucuronide, quercetin-3-O-β-D-xylopyranoside where R₁ is O-β-D-xylopyranose, quercetin-3-O-diglucospyranoside where R₁ is O-diglucospyranose, quercetin-3-O-gentiobioside where R₁ is O-gentiobiose, quercetin-3-O-glucopyranosylgalactopyranoside where R₁ is O-glucopyranosylgalactopyranose, quercetin-3-O-neohesperidoside where R₁ is O-neohesperidose, quercetin-3-O-sophoroside where R₁ is O-sophorose, quercetin-3-gentiotrioside where R₁ is gentiotriose, quercetin-3-methyl ether where R₁ is OCH₃, quercetin-3-rhamnogentiobioside

where R_1 is rhamnogentiobiose, quercetin-3-rhamnoglucoside where R_1 is rhamnoglucose, and quercetin-3-sulfate where R_1 is sulfate; (ii) a derivative group of the formula I wherein R_1 is -OH, three functional groups out of R_2 to R_5 are -OH, and the rest one functional group varies, includes isorhamnetin where R_4 is OCH_3 , quercimeritrin where R_3 is $O-\beta$ -D-glucopyranose, rhamnetin where R_3 is OCH_3 , quercetin-5- $O-\beta$ -D-glucopyranoside where R_2 is $O-\beta$ -D-glucopyranose, quercetin-7- $O-\beta$ -D-glucuronopyranoside where R_3 is $O-\beta$ -D-glucuronopyranose, and spireaoside where R_5 is O-glucose; (iii) a derivative group of the formula I wherein three functional groups out of R_1 to R_5 are OH and the rest two functional groups vary, includes rhamnazin where R_3 and R_4 are OCH_3 , quercetin-3',4'-di-methyl ether where R_4 and R_5 are OCH_3 , quercetin-3,3'-dimethyl ether where R_1 and R_4 are OCH_3 , quercetin-3,7-dimethyl ether where R_1 and R_3 are OCH_3 , quercetin-3- $O-[2''-O-(6'''-O-p-coumaroyl)-\beta$ -D-glucopyranosyl]- α -L-rhamnopyranosyl-7- $O-\beta$ -D-glucopyranoside where R_1 is $O-[2''-O-(6'''-O-p-coumaroyl)-\beta$ -D-glucopyranosyl]- α -L-rhamnopyranose and R_3 is $O-\beta$ -D-glucopyranose, quercetin-3- $O-[2''-O-6'''-O-p-(7'''-O-\beta$ -D-glucopyranosyl)coumaroyl]- β -D-glucopyranosyl]- α -L-rhamnopyranoside-7- $O-\beta$ -D-glucopyranoside where R_1 is $O-[2''-O-6'''-O-p-(7'''-O-\beta$ -D-glucopyranosyl)coumaroyl]- β -D-glucopyranosyl]- α -L-rhamnopyranose and R_3 is $O-\beta$ -D-glucopyranose, quercetin-3- O -rutinoside-7- $O-\beta$ -D-glucopyranoside where R_1 is O-rutinose and R_3 is $O-\beta$ -D-glucopyranose, quercetin-3- $O-\alpha$ -L-arabinopyranosyl-7- $O-\beta$ -D-glucopyranoside where R_1 is $O-\alpha$ -L-arabinopyranosyl and R_3 is $O-\beta$ -D-glucopyranose, quercetin-7- $O-\beta$ -D-glucopyranoside-3- O -sophorose where R_1 is O-sophorose and R_3 is $O-\beta$ -D-glucopyranose, quercetin-3- O -galactopyranosyl-7- O -diglucopyranoside where R_1 is O-galactopyranose and R_3 is O-glucopyranose, quercetin-3- O -glucopyranosyl-7-diglucopyranoside where R_1 is O-glucopyranose and R_3 is O-glucopyranose, quercetin-3,7-diglucopyranoside where R_1 is glucopyranose and R_3 is glucopyranose, quercetin-3-gentiobiosyl-7-glucopyranoside

where R_1 is gentiobiose and R_3 is glucopyranose, and quercetin-3,4'-di-O- β -D-glucopyranoside where R_1 and R_5 are O- β -D-glucopyranose; and (iv) a derivative group of the formula I wherein more than three functional groups vary, includes quercetin-3,4',7-trimethyl ether where R_1 , R_3 and R_5 are OCH_3 , and R_2 and R_4 are OH, and quercetin-3,3',4',7-tetramethyl ether where R_1 , R_3 , R_4 and R_5 are OCH_3 , and R_2 is OH.

Quercetin having same OH groups in R_1 to R_5 of the above general formula(I) is a phenolic compound found in over 4000 kinds of plants in nature and is known as one of the phytoestrogens. It has a molecular formula of $C_{15}H_{10}O_7$ with resonance structures and a molecular weight of 302.33 g/mole and also known as vitamin P following the chemical structure identification in 1936. Quercetin is a rutin, a glycoside wherein sugar is linked via β -linkage and widely distributed in plants such as clover flower, pollen of common ragweed, and shell and stem of various plants, as well as in onion, kale, broccoli, lettuce, tomato, and apple. Quercetin has been verified not only to play an important role in maintenance of capillary wall integrity and capillary resistance(see: Gabor et al., *Plant Flavonoids in Biology and Medicine II: Biochemical, Cellular, and Medical Properties*, 280: 1-15, 1988; Havsteen et al., *Biochemical Pharmacology*, 32:1141-1148, 1983) but also to have antioxidation activity, vitamin P activity, ultraviolet absorbing activity, antihypertensive activity, antiarrhythmic activity, antiinflammatory activity, antiallergic activity, anticholesteremic activity, suppressive activity on liver toxicity, and therapeutic effect on infertility, thus, it may be expected to use quercetin widely in foods, medical and pharmaceutical products, and cosmetics. However, there has been no report on the use of quercetin for prevention and treatment of osteoporosis.

The therapeutic agent for osteoporosis of the invention comprising an active ingredient of quercetin derivative is illustrated below.

5 In order to search for the effects of quercetin derivatives on proliferation of osteoblasts and osteoclasts, the present inventors compared the effect of quercetin with that of phytoestrogen genistein which is known to be an effective agent for treatment of osteoporosis, and have
10 found that quercetin has superior effects to genistein for activation of osteoblast proliferation, increase of alkaline phosphatase activity, and inhibition of osteoclast proliferation.

15 Furthermore, in ovariectomized rats, administration of quercetin derivatives has been found not to bring about changes in hormone level, proving that quercetin is a safe agent not causing uterine hypertrophy, an adverse side effect of estradiol which is being used as a therapeutic
20 agent for osteoporosis currently. Also, quercetin derivatives were shown to be more effective than estradiol on increase of trabecular bone area of tibia which is apt to drastic change in trabecular bone area, and to have no adverse effect on hematopoietic function and immune system.

25 Therefore, quercetin derivatives of the invention, based on above results, have been found not only to have superior effects to currently using phytoestrogen genistein for activation of osteoblast proliferation and inhibition
30 of osteoclast proliferation but also to have little side effects, bring about little change in hormone level and have no adverse effect on hematopoietic function and immune system, substantiating the use of quercetin derivatives as a therapeutic or preventive agent for osteoporosis.

35

Formulation

The said quercetin derivatives having superior effect on treatment of osteoporosis may be mixed with pharmaceutically acceptable excipients including binders such as polyvinylpyrrolidone, hydroxypropylcellulose, etc.,
5 disintegrating agents such as calcium carboxymethylcellulose, sodium glycolate starch, etc., diluting agents such as corn starch, lactose, soybean oil, crystalline cellulose, mannitol, etc., lubricating agents such as magnesium stearate, talc, etc., sweeteners such as
10 sucrose, fructose, sorbitol, aspartame, etc., stabilizing agents such as sodium carboxymethylcellulose, α - or β -cyclodextrin, vitamin C, citric acid, white wax, etc, preservatives such as paraoxymethylbenzoate, paraoxypropylbenzoate, sodium benzoate, etc., and aromatics
15 such as ethylvanillin, masking flavor, flavonomenthol, herb flavor, etc. to prepare pharmaceutical formulations for oral or parenteral administration such as tablets, capsules, soft capsules, liquids, ointments, pills, powders, suspensions, emulsions, syrups, suppositories or injections.
20 Also, to augment efficacy of prevention and treatment of osteoporosis, calcium or vitamin D₃ may be added to the formulations. For parenteral administration of the pharmaceutical preparation of the invention, subcutaneous, intravenous, intramuscular or intraperitoneal injection may
25 be employed. For parenteral administration, quercetin derivative may be mixed with stabilizer or buffer in water to prepare solution or suspension which can be produced as single-dose formulations of ampule or vial.

30 Dosage

The effective amount of quercetin in the therapeutic agent for osteoporosis of the invention is 2 to 20mg/kg, preferably 8 to 12mg/kg, which may be administered to the
35 patient more than once a day depending on the patient's age, gender, degree of seriousness, way of administration, or purpose of prevention.

Safety

The toxicity of the quercetin derivatives of the invention has been reported in the literature(see: M. Sullivan *et al.*, *Proc. Soc. Exp. Biol. Med.*, 77:269, 1951) for the cases of oral administration and intraperitoneal administration to the mice, and LD₅₀ of orally administered quercetin was not less than 160mg/kg, approving that quercetin is safe. In the present invention, liver, kidney, brain, uterus, skin and tibia were examined for the side effect of quercetin, which revealed that the weight of liver, kidney, brain, skin and tibia was not affected, moreover, uterine hypertrophy, a side effect of currently used therapeutic agents, was not observed with quercetin, proving that quercetin derivative as a hormone preparation can be used safely as a therapeutic agent for osteoporosis.

The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.

Example 1: Effect of quercetin on osteoblast proliferation

To analyse the effect of quercetin on osteoblast proliferation, human osteoblast-like cell line Saos-2 was employed and a phytoestrogen genistein was employed as a comparative agent which has been intensively studied as a therapeutic agent for osteoporosis.

Example 1-1: Selection and culture of osteoblasts

Saos-2 cell line which has similar properties to osteoblasts was obtained from Korean Cell Line Bank affiliated to the Cancer Research Institute of School of Medicine, Seoul National University.

Saos-2 cells were seeded in a RPMI 1640 medium(Gibco BRL, U.S.A.) supplemented with 10%(v/v) FBS, 100unit/ml penicillin, 100 μ g/ml streptomycin and grown to form a monolayer in an incubator at 37°C under an environment of 5%(v/v) CO₂ and saturated humidity. The culture was fed with fresh medium 2 to 3 times a week and subcultured once a week using 0.25%(w/v) trypsin.

10 Example 1-2: Cell proliferation depending on concentrations of the agents

Saos-2 cells were distributed into a 96-well plate(20,000 cells/well) and quercetin in 1% DMSO was added to a final concentration of 10⁻² to 10⁻⁹mg/ml, 6 wells per each concentration. As a control group, cells without quercetin were used, and as a comparative group, the cells treated with various concentrations of genistein, being studied as a therapeutic agent for osteoporosis, were used. Cells were grown in an incubator at 37°C for 3 days and incubated 4 more hours under the same condition after adding MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Triazolyl Blue) to a concentration of 0.05mg/ml. Then, purple colored formazan formed in proportion to the number of viable cells was dissolved in DMSO and measured OD at 550nm employing ELISA reader.

Cell proliferation rate(%) was evaluated by calculating the ratio of the OD of quercetin added well to the OD of control well, wherein, average value of ODs from 6 wells treated with the same concentration of quercetin was employed(see: Table 1).

35 cell proliferation rate(%)= {(average value of OD at 550nm of quercetin-treated wells - average value of OD at 550nm

of empty wells)/average value of OD at 550nm of control wells}X100

Example 1-3: Analysis of alkaline phosphatase(ALP) activity

Since osteoblasts have cell specific alkaline phosphatase activity, the effect of quercetin of the invention on ALP activity in osteoblasts was evaluated as follows: the number of cells, concentration of tested agent, and culture condition were same as those used in MTT experiment of Example 1-2, and cells were harvested after 3 day-incubation. Genistein was used as a comparative agent. ALP activity was evaluated by analysing changes of OD at 405nm result from hydrolysis of p-nitrophenylphosphate to p-nitrophenol and phosphate(see: Table 1).

Table 1: Effect of quercetin on osteoblast proliferation

Concentration (mg/ml)	Quercetin (% of control group)		Genistein (% of control group)	
	MTT assay	ALP activity	MTT assay	ALP activity
Control group	100.0 ±2.5	100.0 ±1.6	100.0 ±0.6	100.0 ±7.3
1 ×10 ⁻⁹	93.1 ±0.8*	98.1 ±0.0	91.3 ±0.6*	106.1 ±6.4
1 ×10 ⁻⁸	93.9 ±0.8	104.4 ±3.9	96.9 ±2.7	101.5 ±8.8
1 ×10 ⁻⁷	98.6 ±1.0	101.2 ±3.1	95.9 ±1.6	109.3 ±9.6
1 ×10 ⁻⁶	96.0 ±1.0	127.2 ±3.5**	90.5 ±0.9**	103.8 ±8.7
1 ×10 ⁻⁵	95.8 ±1.1	116.5 ±3.7	97.3 ±1.6	113.5 ±7.3
1 ×10 ⁻⁴	96.5 ±0.8	113.5 ±2.3	95.7 ±0.7	121.1 ±6.2
1 ×10 ⁻³	98.3 ±0.8	107.3 ±1.5	85.5 ±1.1**	98.8 ±6.9
1 ×10 ⁻²	108.6 ±2.2**	106.1 ±4.3	66.2 ±2.8**	62.3 ±3.4

*: p<0.05

**: p<0.01

As shown in Table 1 above, in the cell proliferation experiment using MTT method, the cells treated with various concentrations of quercetin in the range of 1×10^{-9} to 1×10^{-3} mg/ml did not show any difference from the control cells which were not treated with the agent, while quercetin showed maximum cell proliferation effect of 109% of control cell proliferation at a concentration of 1×10^{-2} mg/ml ($p < 0.01$). On the other hand, genistein, a comparative agent, showed 91% ($p < 0.05$) at a concentration of 1×10^{-9} mg/ml, 90.5% ($p < 0.01$) at a concentration of 1×10^{-6} mg/ml, 86% ($p < 0.01$) at a concentration of 1×10^{-3} mg/ml, and 66% ($p < 0.01$) at a concentration of 1×10^{-2} mg/ml, implying that genistein exert rather inhibitory effect than stimulatory effect on proliferation of osteoblasts.

In the experiment of assaying ALP activity, quercetin showed its maximum ALP activation effect of 127% ($p < 0.01$) of control ALP activity at a concentration of 1×10^{-6} mg/ml, while genistein showed its maximum ALP activation activity of 121% at a concentration of 1×10^{-4} mg/ml, indicating that the ALP activation effect of quercetin of the invention is about 100 fold higher than that of genistein. Therefore, quercetin of the invention is more effective on the stimulation of osteoblast proliferation and activation of ALP activity than genistein which is studied intensively as a therapeutic agent for osteoporosis in recent years.

Example 2: Effect of quercetin on osteoclast proliferation

To examine whether quercetin have inhibitory effect on the proliferation of osteoclasts, experiments were carried out as followings.

Example 2-1: Selection and culture of osteoclasts

ICR mice(Korea Research Institute of Chemical Technology, Taejon, Korea) were fed with calcium deficient diet(ICN Biomedicals, Inc., Ohio, U.S.A.) for 4 weeks to activate osteoclasts. The right and left tibiae and femurs of the calcium deficient rats were removed avoiding contamination of surrounding muscle tissues. Femurs and right and left tibiae, classified on the clean bench and kept on ice separately, were added into the α -MEM containing 100 μ g/ml streptomycin and then vigorously shaken respectively to extract osteoclasts into the medium. After kept on ice for 5 minutes, the cell suspension was centrifuged at 800xg for 3 minutes and the cell pellet was resuspended in a α -MEM nutrient medium supplemented with 10% FBS, 100 μ g/ml streptomycin and 100unit/ml penicillin. The cell suspension was distributed into wells of a 24-well plate at a cell number of 3.5×10^6 /well.

Example 2-2: Cell proliferation depending on concentrations of quercetin

20

To the osteoclasts obtained in Example 2-1 above, quercetin was added to yield concentrations of 1×10^{-8} to 1×10^{-2} mg/ml. On day 2, the cells were subjected to tartrate-resistant acid phosphatase(TRAP) staining using a commercially available kit(Sigma Chemical Co., U.S.A.), followed by counting of osteoclasts which are TRAP-positive multinucleated cells(MNC), judged by more than three nuclei in a cell stained red(see: Table 2).

30 Table 2: Effect of quercetin on osteoclast proliferation

Concentration (mg/ml)	Number of osteoclast (% of control group)
Control group	100.0 \pm 8.1
1×10^{-8}	100.9 \pm 1.8
1×10^{-6}	96.8 \pm 2.7
1×10^{-4}	89.6 \pm 3.2

1×10^{-3}	$61.1 \pm 4.1^*$
1×10^{-2}	$24.7 \pm 5.7^{**}$

*: $p < 0.05$,

** : $p < 0.01$

As shown in Table 2 above, while quercetin at
5 concentrations between 1×10^{-8} to 1×10^{-4} mg/ml exerted little
inhibitory effect on the osteoclast proliferation, the
cell numbers at quercetin concentration of 1×10^{-3} mg/ml and
 1×10^{-2} mg/ml was 61% ($p < 0.05$ %) and 25% of control cell number
respectively, showing that quercetin exerted remarkable
10 inhibitory effect on the osteoclast proliferation.

Based on the results of Examples 1 and 2, it was
clearly demonstrated that quercetin is a potential
therapeutic agent for osteoporosis which exerts
15 stimulatory effect on osteoblast proliferation and
inhibitory effect on osteoclast proliferation at a
concentration of 10^{-2} mg/ml.

Example 3: Effect of quercetin on ovariectomized rats

20

Female SD(Sprague-Dawley) rats, a model animal for
type I osteoporosis occurring after menopause were
employed for evaluating pharmacological effectiveness of
quercetin. Female rats(10 weeks old) weighing 200 to 300g,
25 obtained from the Korea Research Institute of Chemical
Technology were employed as experimental animals.
Experiment was carried out by the procedure which
comprises removing ovary, administration of agents to the
each group of rats, and at certain days after ovariectomy,
30 the rats were sacrificed and subjected to analyses
including measurement of body weight, examination of
internal organs, measurement of trabecular bone area,
complete blood count, and biochemical analyses of plasma.

35 Example 3-1: Ovariectomy and administration of the agents

Rats of control group and test group, except Sham group(normal group), were ovariectomized as follows: a female rat was systemic anesthetized by intramuscular
5 injection with 5mg/100g Ketamin(Yuhan Corporation, Korea) and 1mg/100g Xylazine(Beyer Korea, Korea) to the femur muscle of left and right hind limbs, and then, fur of lower abdominal region was shaved, operation area was
10 sterilized with Potadin liquid(Iodine, Samil Pharm. Co., Ltd., Korea) in lying position, about 2cm of abdominal skin, abdominal muscle, and peritoneum was cut in the middle under aseptic condition, ovary was exposed using sterilized forceps, followed by removal of both left and right ovaries after ligaturing of oviducts using silk
15 threads. Subsequently, 0.3ml of antibiotics(Sulfaforte®-4, Yoonee Chemical Co., Ltd., Korea) was injected intraperitoneally to prevent infection, and then peritoneum, abdominal muscle and skin were sutured with silk threads or nylon threads.

20 The Sham group, animals operated upon for the surgery as in the ovariectomized rats except for removing ovary, were employed to compare the changes caused solely by ovariectomy in control group which were ovariectomized but no agent was administered. Control group was employed to
25 compare the changes caused by administration of agents in test group which were ovariectomized and administered with testing agents.

When test agents were administered, for a certain period of time before and after administration, 1.5ml of
30 blood was sampled from tail vein using a catheter(B.D Co.: 24G) and subjected to complete blood count(Coulter Co.: JT) and biochemical analyses of plasma(Crone Co.: Airon® 200). During autopsy, blood was sampled from caudal venae cavae and subjected to the analyses above. And then, each sample
35 was frozen to store for measurement of trabecular bone area of femur and examination of internal organs.

One week after operation, rats in Sham group and control group were intraperitoneally injected with 10% Tween 80 solution, the rats in E2 group were injected with 17β -estradiol at a concentration of $1 \mu\text{g/kg/day}$, the rats in test group were injected with quercetin or genistein at a concentration of 10mg/kg/day for 9 weeks, and the rats in each group were subjected to body weight measurement once a week. During the period of administration, blood was sampled once a week. After 9-week administration, entire blood was withdrawn with heparin treatment. Following complete blood count(CBC), the blood was centrifuged at 3,000rpm for 20 minutes to obtain plasma which was stored at -70°C until use. For measurement of bone mineral density, the lumbar spine L5 and L6, and right tibia were removed and stored separately in 4%(v/v) formalin solution.

Example 3-2: Body weight change depending on quercetin administration

The body weight of the rats in Sham group, E2 group treated with 17β -estradiol and test group treated with quercetin or genistein respectively, was measured once a week for 10 weeks after operation(see: Table 3).

Table 3: Measurement of body weight changes depending on drug administration

Time (week)	Weight(g)				
	Control group	Sham group	E2-treated group	Quercetin-treated group	Genistein-treated group
Before operation	219.39 ± 4.05	220.70 ± 4.63	228.51 ± 8.11	221.87 ± 7.57	217.55 ± 7.24
1 after operation	244.98 ± 3.00	231.51 ± 4.68	249.50 ± 8.16	241.73 ± 4.83	242.12 ± 5.96

2 after operat ion	274.29±3 .68**	236.40±5.0 6##	264.97±8.3 5	271.70±5. 79**	270.00±8.0 5**
3 after operat ion	299.37±3 .74**	245.56±4.7 9###	279.87±8.1 5**	295.00±3. 89**	296.20±7.6 8**
4 after operat ion	315.20±3 .84**	248.96±5.0 2###	292.83±9.2 5**	312.07±5. 95**	310.80±7.8 0**
5 after operat ion	320.30±4 .83**	255.43±5.1 4***	296.96±9.4 4**	320.25±6. 76**	317.29±7.9 3**
6 after operat ion	329.03±5 .05**	261.49±6.4 6***	304.49±8.4 0**	326.68±6. 73**	327.19±8.3 1**
7 after operat ion	337.39±5 .93**	264.78±5.5 3***	313.04±8.7 3**	333.25±7. 61**	332.80±9.2 3**
8 after operat ion	340.01±6 .60**	268.16±5.4 0***	315.87±8.3 2**	335.09±6. 65**	336.38±9.0 1**
9 after operat ion	347.96±7 .58**	273.81±4.5 4***	319.95±9.4 7**	343.02±6. 96**	342.71±8.2 6**
10 after operat ion	356.73±7 .13**	275.22±4.3 0***	320.00±5.9 0**	346.27±6. 39**	347.23±7.5 7**

*: p<0.05, **: p<0.01, compared with before operation

#: p<0.05, ##: p<0.01, compared with control group

As shown in Table 3, body weight of Sham group began to increase 3 weeks (p<0.05) after operation and that of control group began to increase 2 weeks (p<0.01) after operation. That is, control group showed rapid increase of body weight compare to Sham group, and such increase of body weight was slowed down after administration of estradiol, and E2 group showed slower increase of body

weight compare to control group ($p < 0.05$) 20 weeks after operation. Meanwhile, the test group administered with phytoestrogen quercetin or genistein at a concentration of 10mg/kg/day respectively showed rapid increase of body weight even after removing ovary similar to control group. Thus, quercetin administration was found not to bring about meaningful changes in hormone level in the body.

Example 3-3: Changes in the weight of internal organ by quercetin

To find out quercetin effect on internal organ of test animal, liver, kidney, brain, uterus, skin, and tibia were removed from the test animals administered with test agents for 9 weeks after operation and wet weight of each organ was measured (see: Table 4).

Table 4: Changes in the weight of internal organ after drug administration

	Control group	Sham group	E2-treated group	Quercetin-treated group	Genistein-treated group
Liver (g)	9.84±0.3 3	9.52±0.48	9.22±0.4 3	9.07±0.30	10.03±0.36
Kidney (g)	1.95±0.0 9	1.91±0.05	1.85±0.0 9	1.84±0.05	1.83±0.03
Brain (g)	2.03±0.0 4	1.93±0.02	1.98±0.0 5	1.98±0.04	1.98±0.03
Tibia (g)	0.559±0.025	0.514±0.013	0.504±0.019	0.554±0.019	0.537±0.008
Skin (mg)	193±7	169±8	193±6	197±11	188±9
Uterus (mg)	79±4	450±29**	279±10**	85±6	106±3

** : $p < 0.01$

As shown in Table 4, in case of the weight of liver, kidney, brain, tibia, and skin, normal Sham group, ovariectomized control group and test group did not show

differences among groups. However, in case of weight of uterus which is affected by the estrogen secreted from ovary, ovariectomized control group showed significant decrease ($p < 0.01$) compare to Sham group, and administration of E2 after removing ovary suppressed atrophy of uterus ($p < 0.01$) compare to control group. Administration of phytoestrogen quercetin or genistein did not give rise to change in weight of uterus, on the other hand, E2 which is a currently used therapeutic agent for osteoporosis showed side effect such as uterine hypertrophy, showing that quercetin can be used safely as a therapeutic agent for osteoporosis without adverse side effect.

Example 3-4: Changes in the trabecular bone area by quercetin

Trabecular bone area (TBA) of lumbar and tibia removed from the rats of each group which was treated with various agents for 9 weeks were measured as follows: that is, using a digitalizer of quantitative image analysis system (Wild Leitz Co.), image of each trabecula was obtained on computer monitor by drawing a contour of the trabecula, and then, using a computer, calculated were average areas of trabeculae within a rectangle of $2 \times 10^6 \mu\text{m}^2$ area wherein the width is about 2/3 of the length of growth plate which located underneath of growth plate at proximity of tibia. Also, following the number of trabeculae within the rectangle were obtained, average area was multiplied by the number of trabeculae to obtain trabecular bone area of each sample bone, which was analyzed statistically (see: Table 5).

Table 5: Changes in the trabecular bone area of tibia depending on drug administration

	TBA ($\times 10^4 \mu\text{m}^2$)	Change Rate (%)
Control group	34.62 ± 2.62	100.00 ± 7.55

Sham group	85.55 \pm 5.31**	247.07 \pm 15.33**
E2-treated group	51.40 \pm 2.28	148.46 \pm 6.59
Quercetin-treated group	55.52 \pm 7.68*	160.34 \pm 22.17*
Genistein-treated group	47.65 \pm 2.07	137.62 \pm 5.98

*: p<0.05,

**: p<0.01

As shown in Table 5, in case of tibia, the TBA of control group was $34.62 \times 10^4 \mu\text{m}^2$ which is a significantly decreased value compare to normal Sham group of $85.55 \times 10^4 \mu\text{m}^2$ (p<0.01), showing that osteoporosis have occurred in control group, and such decreased TBA was increased again by treatment with E2, quercetin or genistein to 148%, 160%, and 138% of TBA of control group respectively, especially in case of quercetin, remarkable increase of TBA was monitored (p<0.05).

TBAs of lumbar removed from the animal treated with test agents for 9 weeks were measured employing the same method above (see: Table 6).

Table 6: Changes in the trabecular bone area of lumbar depending on drug administration

	TBA ($\times 10^4 \mu\text{m}^2$)	Change Rate (%)
Control group	67.53 \pm 2.31	100.00 \pm 3.42
Sham group	93.70 \pm 5.29**	138.76 \pm 7.84**
E2-treated group	89.16 \pm 2.83**	132.04 \pm 4.19**
Quercetin-treated group	87.38 \pm 4.53*	129.40 \pm 6.71*
Genistein-treated group	86.58 \pm 3.00*	128.23 \pm 4.45*

*: p<0.05,

**: p<0.01

As shown in Table 6, in case of lumbar, the TBA of control group was $67.53 \times 10^4 \mu\text{m}^2$ which is a decreased value compare to Sham group of $93.70 \times 10^4 \mu\text{m}^2$ ($p < 0.01$), but, such decreased TBA was increased again by treatment with E2, quercetin or genistein to 132% ($p < 0.01$), 129% ($p < 0.05$) and 128% ($p < 0.05$) of TBA of control group respectively, showing that these test agents exerted suppressing effect on decrease of TBA caused by ovariectomy. Especially, quercetin showed more significant increase of TBA in tibia which is apt to drastic change in TBA than E2 a currently used therapeutic agent for osteoporosis, showing that quercetin is a more effective therapeutic agent not causing uterine hypertrophy which is an adverse side effect caused by E2.

Example 3-5: Complete blood count

Complete blood count which reflects the condition and abnormality of the body was measured to find out abnormality in test animals caused by administration of agents. That is, to find out changes in hematopoiesis of test rats, measured were red blood cell (RBC) count, concentration of hemoglobin (Hb) and hematocrit (Ht) of blood samples obtained from the rats prior to operation and the rats 10 weeks after administering agents following operation, and to find out changes in immune system such as inflammation and necrosis of tissues, measured were white blood cell count, lymphocyte count, monocyte count, and granulocyte count (see: Table 7).

Table 7: Changes in Complete blood count depending on drug administration

	Operation	Control group	Sham group	E2-treated group	Quercetin-treated group	Genistein-treated group
Red blood cell (RBC) count ($\times 10^6$ cells/ μ l)	before	7.36 \pm 0.11	7.19 \pm 0.11	7.33 \pm 0.13	7.29 \pm 0.15	7.32 \pm 0.13
	after	7.08 \pm 0.09	6.75 \pm 0.24	6.97 \pm 0.14	7.13 \pm 0.15	7.17 \pm 0.13
Concentration of hemoglobin (Hb) (g/dl)	before	16.09 \pm 0.21	15.75 \pm 0.20	15.86 \pm 0.24	16.00 \pm 0.30	15.82 \pm 0.27
	after	14.58 \pm 0.20**	14.09 \pm 0.48**	14.34 \pm 0.29**	14.84 \pm 0.22*	14.70 \pm 0.22**
Hematocrit (Ht) (%)	before	43.34 \pm 0.48	43.09 \pm 0.61	43.11 \pm 0.55	43.62 \pm 0.83	42.76 \pm 0.65
	after	39.48 \pm 0.60**	38.39 \pm 0.24**	38.86 \pm 0.72**	41.10 \pm 0.68*	40.66 \pm 0.56*
White blood cell count ($\times 10^3$ cells/ μ l)	before	26.13 \pm 4.63	25.61 \pm 3.64	23.14 \pm 1.50	20.28 \pm 3.77	27.30 \pm 4.85
	after	21.66 \pm 2.89	12.74 \pm 2.88*	13.26 \pm 0.97**	18.50 \pm 7.60	21.50 \pm 2.53
Lymphocyte count ($\times 10^3$ cells/ μ l)	before	22.14 \pm 4.49	18.04 \pm 2.38	17.80 \pm 1.72	16.78 \pm 3.52	19.68 \pm 4.52
	after	21.20 \pm 9.00	10.20 \pm 2.88	10.23 \pm 0.96**	15.00 \pm 7.71	15.25 \pm 3.21
Monocyte count ($\times 10^3$ cells/ μ l)	before	1.02 \pm 0.18	0.73 \pm 0.17	1.44 \pm 0.29	0.65 \pm 0.07	0.77 \pm 0.09
	after	1.10 \pm 0.21	0.95 \pm 0.14	1.02 \pm 0.24	1.00 \pm 0.20	0.80 \pm 0.19
Granulocyte count ($\times 10^3$ cells/ μ l)	before	2.99 \pm 0.44	2.83 \pm 0.39	3.67 \pm 0.40	2.80 \pm 0.30	2.23 \pm 0.10
	after	2.52 \pm 0.21	1.93 \pm 0.26	1.99 \pm 0.25**	2.43 \pm 0.12	2.38 \pm 0.37

*: $p < 0.05$,

5 **: $p < 0.01$

As shown in Table 7, RBC count did not show any changes before and after operation in all groups, and concentration of hemoglobin and hematocrit were decreased after operation in all groups. White blood cell count did not show any changes before and after operation in quercetin or genistein treated groups, but decreased in Sham group and E2 group after operation. Also, lymphocyte

and granulocyte count showed rapid decrease in E2 group only, and monocyte count was stayed same in entire groups. Thus, quercetin was found to be a safe agent not disturbing hematopoiesis and immune system of the body.

5

Example 3-6: Biochemical changes of plasma by quercetin

Since blood reflects the condition of body, safety of quercetin in the body was evaluated by measuring biochemical parameters: that is, blood samples were obtained from the rat prior to operation, one week after operation, and 10 weeks after operation, and measured were levels of alkaline phosphatase (ALP), calcium, inorganic phosphate, blood urea nitrogen (BUN), creatinin, total cholesterol, HDL-cholesterol and LDL-cholesterol (see: Table 8).

Table 8: Changes in biochemical parameters in plasma depending on drug administration

	Operation	Control group	Sham group	E2-treated group	Quercetin-treated group	Genistein-treated group
Concentration of ALP (U/dL)	before	262.75±23 .31	245.59±22 .05	196.01±28 .34	232.83±20 .27	208.86±19.72
	1 week after	265.75±22 .78	215.18±20 .22	195.24±27 .87	226.67±23 .20	212.10±17.92
	10 weeks after	198.31±14 .64	135.09±18 .64 ^{##}	123.99±22 .18	156.42±13 .08	127.14±9.95 ^{##}
Concentration of calcium (mg/dL)	before	10.48±0.4 3	10.57±0.5 5	10.86±0.4 0	10.73±0.4 8	10.61±0.49
	1 week after	9.98±0.34	10.35±0.1 7	10.03±0.1 8	8.37±0.24 ^{##}	8.97±0.29 [#]
	10 weeks after	10.83±0.1 6	11.79±0.2 3 ^s	11.20±0.1 6 ^s	10.26±0.1 9 ^s	10.44±0.22 ^s
Concentration of inorganic phosphate (mg/dL)	before	6.52±0.39	6.87±0.62	6.90±0.52	6.79±0.66	7.18±0.48
	1 week after	6.27±0.31	6.59±0.20	6.13±0.12	6.21±0.18	6.47±0.16
	10 weeks after	4.95±0.41 ^{##}	6.09±0.47	5.51±0.45	5.73±0.58	5.62±0.25 [#]

Concentration of blood urea nitrogen (BUN) (mg/dL)	before	18.56±0.9 2	17.13±1.1 1	18.36±1.0 1	17.05±0.6 0	16.82±0.60
	1 week after	18.31±0.7 0	16.75±0.5 8	17.79±0.7 6	18.06±0.8 8	18.26±0.94
	10 weeks after	21.20±1.0 6	19.23±0.8 4	19.99±0.8 6	18.19±0.4 1	18.31±0.86
Concentration of creatinin (mg/dL)	before	0.54±0.05	0.56±0.06	0.55±0.05	0.57±0.05	0.51±0.04
	1 week after	0.54±0.05	0.62±0.04	0.57±0.03	0.59±0.01	0.64±0.02*
	10 weeks after	0.78±0.03 ###	0.80±0.03 ##	0.81±0.03 ###	0.82±0.04 ###	0.82±0.04 ^{##} \$
Concentration of total cholesterol (mg/dL)	before	72.66±5.0 0	79.67±1.7 3	76.79±2.8 0	77.55±5.1 3	85.51±5.45
	1 week after	93.32±4.7 5 [#]	79.75±2.4 6	95.53±4.1 7	85.84±3.8 2	91.56±3.65
	10 weeks after	120.44±5.21 ^{###}	88.60±4.8 7 ^{**}	115.05±5.75 ^{###}	107.73±2.24 ^{##}	121.07±6.53 ^{##}
Concentration of HDL-cholesterol (mg/dL)	before	53.78±2.7 7	52.33±2.6 1	52.30±2.0 1	53.38±3.1 4	61.12±3.57
	1 week after	46.20±0.6 2	41.69±1.4 7	49.03±3.3 7	42.49±4.8 5	35.26±1.92 [#]
	10 weeks after	29.60±2.6 3 ^{###}	22.32±2.4 9 ^{###}	24.94±2.7 2 ^{###}	25.13±2.7 8 ^{##}	29.27±1.98 [#]
Concentration of LDL-cholesterol (mg/dL)	before	18.88±3.1 5	26.63±3.0 4	24.49±1.6 3	24.17±3.1 3	24.39±3.63
	1 week after	42.80±6.4 1 ^{##}	36.30±0.6 3	40.50±6.1 7	40.85±4.8 8	60.47±7.04 [#]
	10 weeks after	90.84±4.2 7 ^{###}	69.29±3.0 5 ^{###}	88.33±4.7 4 ^{###}	82.60±4.8 5 ^{###}	91.80±6.57 [#] ###

*: p<0.05, **: p<0.01, compared with control group

#: p<0.05, ##: p<0.01, compared with before operation

\$: p<0.05, \$\$: p<0.01, compared with 1 week after operation

5 As shown in Table 8, ALP activity which is directly related to bone metabolism showed tendency of decrease with aging in entire groups, especially, in Sham group and genistein treated group, the rats of 10 weeks after operation showed significant decrease of ALP activity and
10 no change in calcium concentration compare to the rats prior to operation and one week after operation. And, the level of inorganic phosphate remarkably decreased in the

rats of 10 weeks after operation compare to the rats prior to operation in control group and genistein treated group.

While the level of blood urea nitrogen which is related to the protein metabolism and muscle volume was maintained at a proper level in entire groups, the level of creatinin increased in entire groups.

The level of total cholesterol which is known to increase in postmenopause women increased in entire groups, although increase in Sham group was relatively low. While the level of HDL-cholesterol decreased with time in entire groups, the level of LDL-cholesterol increased with time, which were found in normal Sham group as well as ovariectomized groups.

Thus, the quercetin of the invention was found to be an effective therapeutic and preventive agent for osteoporosis.

Example 4: The formulation of the quercetin preparation

Example 4-1: Syrup

The syrup formulation containing 2%(w/v) quercetin, its derivatives or pharmaceutically acceptable salts thereof was prepared as follows: quercetin hydrochloride, saccharine and sugar were dissolved in 80g of warm water, cooled down, and then mixed with a solution containing glycerin, saccharine, aromatics, ethanol, sorbic acid and distilled water. Water was added to the mixture prepared above to give 100ml of syrup formulation of quercetin, whose components are as follows:

quercetin hydrochloride	2g
saccharine	0.8g
sugar	25.4g
glycerin	8.0g
aromatics	0.04g
ethanol	4.0g

sorbic acid 0.4g
distilled water a proper quantity

Example 4-2: Tablet

5

The tablet containing quercetin, its derivatives or pharmaceutically acceptable salts thereof was prepared as follows: 250g of flavonoid derivative of quercetin hydrochloride was mixed with 175.9g of lactose, 10 180g of potato starch, and 32g of colloidal silicate, and then 10%(w/v) gelatin solution was added. After pulverization, the mixture was passed through a 14-mesh sieve, dried, and mixed with 160g of potato starch, 50g of talc, and 5g of magnesium stearate to give tablets, whose 15 components are as follows:

flavonoid derivative of quercetin hydrochloride 250g
lactose 175.9g
potato starch 180g
20 colloidal silicate 32g
10%(w/v) gelatin solution a proper quantity
potato starch 160g
talc 50g
magnesium stearate 5g

25

Example 4-3: Injection

One gram of flavonoid derivative of quercetin hydrochloride, 0.6g NaCl, and 0.1g of ascorbic 30 acid were dissolved in distilled water to give a final volume of 100ml, and then the solution was put into a vial, which was sterilized by heating at 100°C for 30 minutes to give the injection. The components of the said injection are as follows:

35


flavonoid derivative of quercetin hydrochloride1g
NaCl 0.6g

ascorbic acid 0.1g
distilled water a proper quantity

As clearly illustrated and demonstrated above, the
5 present invention provides a therapeutic agent for
osteoporosis comprising an active ingredient of quercetin
derivatives which effectively stimulate osteoblast
proliferation and inhibit osteoclast proliferation. The
quercetin derivatives of the invention can be practically
10 applied for the treatment and prevention of osteoporosis,
since they effectively inhibit osteoclast proliferation and
stimulate osteoblast proliferation more than conventional
therapeutic agents for osteoporosis, and increase
trabecular bone area highly without changing hormone level
15 in body and untoward effects on hematopoietic function and
immune system.

WHAT IS CLAIMED IS:

1. A therapeutic agent for osteoporosis comprising an active ingredient of quercetin derivatives represented by the following general formula(I) and a pharmaceutically acceptable carrier:



wherein,

R_1 is gentiotriose, glucopyranose, O-arabinofuranose, O-diglucopyranose, O-galactopyranose, O-galactoside-gallate, O-gentiobiose, O-glucopyranose, O-glucuronide, O-neohesperidose, O-rhamnopyranose, O-rutinose, O-sophorose, O-xylopyranose, OCH_3 , OH, rhamnogentiobiose, rhamnoglucose or sulfate;

R_2 is OH or O-glucopyranose;

R_3 is OCH_3 , OH, O-glucopyranose, O-glucuronopyranose or glucopyranose;

R_4 is OCH_3 or OH; and,

R_5 is OCH_3 , OH, O-glucopyranose or O-glucose.

20

2. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivatives are compounds represented by general formula(I) whose R_2 , R_3 , R_4 and R_5 are -OH as followings: quercetin, avicularoside, guiajaverin, hyperoside, isohyperoside, isoquercitrin, multinoside A, multinoside A acetate, quercitrin, rutin, quercetin-3-O-

25

(2"-O-β-D-glucopyranosyl)-α-L-rhamnopyranoside, quercetin-3-O-(6"-O-galloyl)-glucopyranoside, quercetin-3-O-(6'"-O-p-coumaroyl-β-D-glucopyranosyl-(1-2)-α-L-rhamnopyranoside), quercetin-3-O-D-glucopyranosyl-(1-6)-β-D-glucopyranosyl-(1-4)-α-L-rhamnopyranoside, quercetin-3-O-[2"-O-6'"-O-p-(7'"-O-β-D-glucopyranosyl)coumaroyl-β-D-glucopyranosyl]-α-L-rhamnopyranoside, quercetin-3-O-[6'"-p-coumaroyl-β-D-glucopyranosyl-β-(1-4)-rhamnopyranoside], quercetin-3-O-[α-L-rhamnopyranosyl(1-2)-α-L-rhamnopyranosyl-(1-6)-β-D-glucopyranoside], quercetin-3-O-[α-rhamnopyranosyl(1-4)α-L-rhamnopyranosyl(1-6)β-D-galactopyranoside], quercetin-3-O-[α-rhamnopyranosyl-(1-2)]-[β-glucopyranosyl-(1-6)]-β-D-galactopyranoside, quercetin-3-O-[α-rhamnopyranosyl-(1-4)-α-rhamnopyranosyl-(1-6)-β-galactopyranoside], quercetin-3-O-α-L-rhamnopyranosyl-(1-2)-β-D-galactopyranoside, quercetin-3-O-β-D-diglucopyranoside, quercetin-3-O-β-D-galactoside-2"-gallate, quercetin-3-O-β-D-glucopyranoside-(1-6)-β-D-galactopyranoside, quercetin-3-O-β-D-glucopyranosyl-(1-3)-α-L-rhamnopyranosyl-(1-6)-β-D-galactopyranoside, quercetin-3-O-β-D-glucuronide, quercetin-3-O-β-D-xylopyranoside, quercetin-3-O-diglucospyranoside, quercetin-3-O-gentiobioside, quercetin-3-O-glucopyranosylgalactopyranoside, quercetin-3-O-neohesperidoside, quercetin-3-gentiotrioside, quercetin-3-methyl ether, quercetin-3-rhamnogentiobioside, quercetin-3-rhamnoglucoside, or quercetin-3-sulfate.

3. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivatives are compounds represented by general formula(I) whose R₁ is -OH and three functional groups out of R₂, R₃, R₄ and R₅ are -OH as followings: isorhamnetin, quercimeritrin, rhamnetin, quercetin-5-O-β-D-glucopyranoside, quercetin-7-O-β-D-glucuronopyranoside or spireaoside.

4. The therapeutic agent for osteoporosis of claim 1,

wherein the quercetin derivatives are compounds represented by general formula(I) whose three functional groups out of R_1 , R_2 , R_3 , R_4 and R_5 are -OH as followings: rhamnazin, quercetin-3',4'-di-methyl ether, quercetin-3,3'-dimethyl ether, quercetin-3,7-dimethyl ether, quercetin-3-O-[2"-O-(6'"-O-p-coumaroyl)- β -D-glucopyranosyl]- α -L-rhamnopyranosyl-7-O- β -D-glucopyranoside, quercetin-3-O-[2"-O-6'"-O-p-(7'"-O- β -D-glucopyranosyl) coumaroyl- β -D-glucopyranosyl]- α -L-rhamnopyranoside-7-O- β -D-glucopyranoside, quercetin-3-O-rutinoside-7-O- β -D-glucopyranoside, quercetin-3-O- α -L-arabinopyranosyl-7-O- β -D-glucopyranoside, quercetin-7-O- β -D-glucopyranoside-3-O-sophoroside, quercetin-3-O-galactopyranosyl-7-O-diglucopyranoside, quercetin-3-O-glucopyranosyl-7-diglucopyranoside, quercetin-3,7-diglucopyranoside, quercetin-3-gentiobiosyl-7-glucopyranoside or quercetin-3,4'-di-O- β -D-glucopyranoside.

5. The therapeutic agent for osteoporosis of claim 1, wherein the quercetin derivative is quercetin-3,4',7-trimethyl ether or quercetin-3,3',4',7-tetramethyl ether.

6. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of polyvinylpyrrolidone and hydroxypropylcellulose.

7. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is a disintegrating agent selected from the group consisting of calcium carboxymethylcellulose and sodium glycolate starch.

8. The therapeutic agent for osteoporosis of claim 1, wherein the pharmaceutically acceptable carrier is a diluting agent selected from the group consisting of corn starch, lactose, soybean oil, crystalline cellulose and mannitol.

9. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
lubricating agent selected from the group consisting of
5 magnesium stearate and talc.

10. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
sweetener selected from the group consisting of sucrose,
10 fructose, sorbitol and aspartame.

11. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
stabilizing agent selected from the group consisting of
15 sodium carboxymethylcellulose, α - or β -cyclodextrin,
vitamin C, citric acid and white wax.

12. The therapeutic agent for osteoporosis of claim 1,
wherein the pharmaceutically acceptable carrier is a
20 preservative selected from the group consisting of
paraoxymethylbenzoate, paraoxypropylbenzoate and sodium
benzoate.

13. The therapeutic agent for osteoporosis of claim 1,
25 wherein the pharmaceutically acceptable carrier is an
aromatic selected from the group consisting of
ethylvanillin, masking flavor, flavonomenthol and herb
flavor.

30 14. The therapeutic agent for osteoporosis of claim 1,
wherein the therapeutic agent is a pharmaceutical
formulation for oral or parenteral administration selected
from the group consisting of tablets, capsules, soft
capsules, liquids, ointments, pills, powders, suspensions,
35 emulsions, syrups, suppositories and injections.

15. The therapeutic agent for osteoporosis of claim 1
which further comprises calcium or vitamin D₃.

5

10

15

20

25

30

35

A. CLASSIFICATION OF SUBJECT MATTER IPC7 A61K 31/353 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC7: C07D; A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CASLINK; ESPACENET		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 63-156720 A (KISSEI CO.) 29. 06. 88, see the whole document, (Family; none)	1-15
A	WO 95/03293 A (CHINOIN LTD.) 02. 02. 95, see the whole document	1-15
A	JP 60-048924 A (TAKETA LTD.) 16. 03. 85, see the whole document	1-15
A	US 6,040,333 A (SHERRY D.) 21. 03.00, see the whole document, (Family; none)	1-15
A	Fiorelli, G. et al., "Estrogen synthesis in human colon cancer epithelial cells", In; J. Steroid Biochem. Mol. Biol., 1999, 71(5-6), 223-230.	1-15
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 27 JUNE 2001 (27.06.2001)		Date of mailing of the international search report 29 JUNE 2001 (29.06.2001)
Name and mailing address of the ISA/KR Korean Intellectual Property Office Government Complex-Daejeon, Dunsan-dong, Seo-gu, Daejeon Metropolitan City 302-701, Republic of Korea Facsimile No. 82-42-472-7140		Authorized officer LEE, Yu Hyung Telephone No. 82-42-481-5603



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR01/00368

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 95/03293 A	02. 02. 95	AU 7236794 A	20. 02. 95
		CA 2167597 A	02. 02. 95
		CN 1129445 A	21. 08. 96
		EP 710234 A	08. 05. 96
		HU 68558 A	28. 06. 95
.....			
JP 60-048924 A	16. 03. 85	DE 3430799 A	14. 03. 85
		EP 135172 A	27. 03. 85
		IT 1179067 A	16. 09. 87
.....			